Reference materials for cellular therapeutics

被引:8
作者
Bravery, Christopher A. [1 ]
French, Anna [2 ]
机构
[1] Consulting Adv Biol Ltd, Adv Biol Ltd, London E1 4EW, England
[2] Univ Oxford, Oxford UCL Ctr Adv Sustainable Med Innovat CASMI, Oxford, England
关键词
reference materials; cellular therapeutics; metrology; standards; ASSAYS PRACTICE GUIDELINES; FLOW-CYTOMETRY; ICSH; VALIDATION; ICCS; STANDARDS; LYMPHOCYTES; CRITERIA; ISSUES; CELLS;
D O I
10.1016/j.jcyt.2014.05.024
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The development of cellular therapeutics (CTP) takes place over many years, and, where successful, the developer will anticipate the product to be in clinical use for decades. Successful demonstration. of manufacturing and quality consistency is dependent on the use of complex analytical methods; thus, the risk of process and method drift over time is high. The use of reference materials (RM) is an established scientific principle and as such also a regulatory requirement. The various uses of RM. in the context of CTP manufacturing and quality are discussed, along with why they are needed for living cell products and the analytical methods applied to them. Relatively few consensus RM exist that are suitable for even common methods used by CTP developers, such as flow cytometry. Others have also identified this need and made proposals; however, great care will be needed to ensure any consensus RM that result are fit for purpose. Such consensus RM probably will need to be applied to specific standardized methods, and the idea that a single RM can have wide applicability is challenged. Written standards, including standardized methods, together with appropriate measurement RM are probably the most appropriate way to define specific starting cell types. The characteristics of a specific CTP will to some degree deviate from those of the starting cells; consequently, a product RM remains the best solution where feasible. Each CTP developer must consider how and what types of RM should be used to ensure the reliability of their own analytical measurements.
引用
收藏
页码:1187 / 1196
页数:10
相关论文
共 28 条
[1]   The role of standards in innovation [J].
Allen, RH ;
Sriram, RD .
TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE, 2000, 64 (2-3) :171-181
[2]   The external RNA controls consortium: a progress report [J].
Baker, SC ;
Bauer, SR ;
Beyer, RP ;
Brenton, JD ;
Bromley, B ;
Burrill, J ;
Causton, H ;
Conley, MP ;
Elespuru, R ;
Fero, M ;
Foy, C ;
Fuscoe, J ;
Gao, XL ;
Gerhold, DL ;
Gilles, P ;
Goodsaid, F ;
Guo, X ;
Hackett, J ;
Hockett, RD ;
Ikonomi, P ;
Irizarry, RA ;
Kawasaki, ES ;
Kaysser-Kranich, T ;
Kerr, K ;
Kiser, G ;
Koch, WH ;
Lee, KY ;
Liu, CM ;
Liu, ZL ;
Lucas, A ;
Manohar, CF ;
Miyada, G ;
Modrusan, Z ;
Parkes, H ;
Puri, RK ;
Reid, L ;
Ryder, TB ;
Salit, M ;
Samaha, RR ;
Scherf, U ;
Sendera, TJ ;
Setterquist, RA ;
Shi, LM ;
Shippy, R ;
Soriano, JV ;
Wagar, EA ;
Warrington, JA ;
Williams, M ;
Wilmer, F ;
Wilson, M .
NATURE METHODS, 2005, 2 (10) :731-734
[3]   Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part IV - Postanalytic Considerations [J].
Barnett, David ;
Louzao, Raul ;
Gambell, Peter ;
De, Jitakshi ;
Oldaker, Teri ;
Hanson, Curtis A. .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2013, 84 (05) :309-314
[4]  
Barwick VJ, 2011, EURACHEM GUIDE TERMI
[5]   Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry [J].
Bravery, Christopher A. ;
Carmen, Jessica ;
Fong, Timothy ;
Oprea, Wanda ;
Hoogendoorn, Karin H. ;
Woda, Juliana ;
Burger, Scott R. ;
Rowley, Jon A. ;
Bonyhadi, Mark L. ;
Van't Hof, Wouter .
CYTOTHERAPY, 2013, 15 (01) :9-19
[6]  
BSI, 2012, REGEN MED, V7, pS1
[7]   Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part I - Rationale and Aims [J].
Davis, Bruce H. ;
Wood, Brent ;
Oldaker, Teri ;
Barnett, David .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2013, 84 (05) :282-285
[8]   Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part II - Preanalytical Issues [J].
Davis, Bruce H. ;
Dasgupta, Amar ;
Kussick, Steven ;
Han, Jin-Yeong ;
Estrellado, Annalee .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2013, 84 (05) :286-290
[9]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[10]  
Ellison SLR., 2012, Quantifying uncertainty in analytical measurement